Nordic Life Science Days 2017, the region’s premier partnering event, this year in the heart of Medicon Valley
Diabetes Game Changers, Funding Excess Trials and the Added Value of De Novo Service Provider Research – NLSD Super Sessions Tackle the Big Questions
With 10 weeks to go and delegate numbers at an all-time high, Nordic Life Science Days again looks set to be a major success as it heads on September 12-14 to Malmö, in the heart of Medicon Valley. As well as providing a 360 view of the thriving Nordic Life Science scene – companies, service providers, investors, research communities, and government and regulatory bodies – the 2-day event also tackles the issues facing the sector. The Super Sessions in particular spark lively debate and this year’s topics look sure to continue the tradition.
“We’ve canvassed our members and networks extensively and this year I believe come up with an unmissable programme. In particular, I would recommend three of the Super Sessions – Diabetes Game Changers, Funding Excess Trials and Tapping the Potential of De Novo Service Provider Research,” says Jonas Ekstrand, Director General of SwedenBIO, the Swedish life science industry organization which founded the event five years ago with Bionordic.
Diabetes is Super Session I and deals with game changers in diabetes treatment. Diabetes research has long been a strength in the Nordic region, where especially Denmark has played a leading role. The belief is now we are entering an era of potentially disruptive solutions and so the session will focus on new developments such as closed loop systems and ultrafast acting insulins and their impact on patients with unstable blood glucose.
Super Session 4 seeks to open the way to new methods of funding excess clinical stage projects. Increasingly biopharma companies find they have built pipelines that offer more development opportunities than their resources allow them to pursue. This can result in promising clinical trials being moved down the priority list and their execution delayed – leading to a decline in asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaborations with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. While there are several potential advantages of this approach, the session will also address more difficult questions such as: What would be the primary driving forces for different parties to engage in this type of collaboration? Are there also complications with the phenomenon? How does an excess of promising assets within large biopharma companies affect other parts of the life science ecosystem?
Finally, Super Session 5 will seek to raise awareness of the large amount of de novo research carried out by service providers and its added value to client companies. They provide much more than just an extra pair of hands, often spending large amounts on in house development of their services. This in turn enables smaller biopharmas to concentrate on core competencies.
“NLSDays also takes place during a thriving period for the Nordic region. For example, last year’s pipeline report on drug development activities in Sweden presented a record-high 367 projects, of which 60% were preclinical. Thus, the current trend for pharma companies to look for collaborations earlier and earlier in the value chain makes NLSDays increasingly relevant as a life science partnering event.”, continues Ekstrand, “We are also hoping that the EMA will relocate here.”
There will also be a pre-conference fringe on September 12thwith two main events. First a coach tour to Lund, only 20 km outside Malmö to visit the recently inaugurated MAX IV facility and the under construction ESS. And then, don’t miss the Academic’s Catwalk and the Startups’ Challenge just before the Welcome Get Together.
NLSDays is a SwedenBIO event, produced by Bionordic. Nordic Life Science Days has grown rapidly since its launch in 2012 to become the largest Nordic partnering conference for the global life science industry. In 2016, 1,070 delegates from 36 countries attended the meeting. The 680 companies attending engaged in over 2,000 one-on-one meetings.
Among the investors and big pharma registered for the meeting so far include AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cadila, Daiichi Sankyo, Novo Nordisk, Pfizer, Roche, Servier, Sanofi and Johnson & Johnson
Venue: Malmömässan, Mässgatan 6, 215 32 Malmö, Sweden.
Time: September 12-14, 2017
Nordic Life Science Days is a SwedenBIO event produced by Bionordic.
General information: Olivier Duchamp, email@example.com., +33 (0) 608 804 515.
Regarding the conference program: firstname.lastname@example.org., +46 (0) 708 111 268.
Media-related: Ola Björkman, email@example.com., +46 (0) 70 245 74 97.
About SwedenBIO, http://swedenbio.se/information-in-english/
SwedenBIO, the trade association for the Swedish life science sector has more than 200 members operating across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves to the benefit the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to contribute to improving the conditions for the life science industry for the benefit of industry growth and business development. Sweden’s life science industry accounts for 20% of Sweden's net exports.
About Bionordic, http://www.bionordic.com
Bionordic is a full service global event management company that designs, plans and produces engaging conferences and corporate events for the life science industry. The organization supports a broad range of global clients including public and private agencies, non-governmental organizations, regional and multinational corporations.
Based on cutting edge technology solutions, Bionordic offer event services including strategic planning, venue selection and design through to cloud and database and community management tools.